Navigation Links
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Date:5/18/2009

Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

About Oak Investment Partners

Oak Investment Partners is a multi-stage venture capital firm with a total of $8.4 billion in committed capital. The primary investment focus is on high growth opportunities in Healthcare Information and Services, Information Technology and Software Outsourced Services, Consumer Internet/New Media, Financial Services Technology, Clean Energy, Broadband Internet and Wireless Communications, and Retail. Over a 30-year history, Oak has achieved a strong track record as a stage-independent investor funding more than 481 companies at key points in their lifecycles. Oak has been involved in the formation of companies, funded spinouts of operating divisions and technology assets, and provided growth equity to mid- and late-stage private businesses
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
3. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Clarient to Commercialize Novel Breast Cancer Profile
9. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... HILLS, Mass., Dec. 5 MacroChem,s,(OTC Bulletin Board: MACM), ... at the upcoming Equities Magazine Winter Discovery,Day Conference XV ... December 7,2007. Mr. DeLuccia is scheduled to present at ... an all day event featuring special,presentations from emerging public ...
... Md., Dec. 5 Micromet, Inc. (Nasdaq:,MITI), a ... antibody-based products for cancer, inflammation and autoimmune,diseases, today ... Officer of Micromet, will be part of a ... Therapies For Cancer" at the 2007,RBC Capital Markets ...
... Dec. 5 Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ... study with an undisclosed global leader in the production ... Factor IX protein,which is currently administered by injection to ... "We look forward to working with our new global ...
Cached Biology Technology:MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 2MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 3Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007 2Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... 21 researchers from 11 nations, including professor Robert "JJ" Orth ... first-ever study of the risk of extinction for individual seagrass ... the International Union for the Conservation of Nature (IUCN), shows ... at an elevated risk of extinction, while 3 species qualify ...
... who reported not taking a daily prenatal vitamin immediately before ... as likely to have a child with an autism spectrum ... the associated risk rose to seven times as great when ... at the UC Davis MIND Institute has found. "Mothers ...
... body against infection don,t huff and puff, but some ... against infection don,t huff and puff, but some of ... steam engine. Weizmann Institute scientists have discovered a mechanism ... when the inflammatory mechanism that protects cells against viruses ...
Cached Biology News:New study provides global analysis of seagrass extinction risk 2Women who start prenatal vitamins early are less likely to have children with autism 2Women who start prenatal vitamins early are less likely to have children with autism 3Women who start prenatal vitamins early are less likely to have children with autism 4Immune system release valve 2
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
... Mouse monoclonal [E12] to MAP1 Light Chain ... the physical interactions between microtubules and components of ... a heavy chain subunit and multiple light chain ... one of the light chain subunits and can ...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: